title: Insulin action on heart and skeletal muscle glucose uptake in essential hypertension.
abstract: Essential hypertension is characterized by skeletal muscle insulin resistance but it is unknown whether insulin resistance also affects heart glucose uptake. We quantitated whole body (euglycemic insulin clamp) and heart and skeletal muscle (positron emission tomography and 18F-fluoro-2-deoxy-D-glucose) glucose uptake rates in 10 mild essential hypertensive (age 33 +/- 1 yr, body mass index 23.7 +/- 0.8 kg/m2, blood pressure 146 +/- 3/97 +/- 3 mmHg, VO2max 37 +/- 3 ml/kg per min) and 14 normal subjects (29 +/- 2 yr, 22.5 +/- 0.5 kg/m2, 118 +/- 4/69 +/- 3 mmHg, 43 +/- 2 ml/kg per min). Left ventricular mass was similar in the hypertensive (155 +/- 15 g) and the normotensive (164 +/- 13 g) subjects. In the hypertensives, both whole body (28 +/- 3 vs 44 +/- 3 mumol/kg per min, P < 0.01) and femoral (64 +/- 11 vs 94 +/- 8 mumol/kg muscle per min, P < 0.05) glucose uptake rates were decreased compared to the controls. In contrast, heart glucose uptake was 33% increased in the hypertensives (939 +/- 51 vs 707 +/- 46 mumol/kg muscle per min, P < 0.005), and correlated with systolic blood pressure (r = 0.66, P < 0.001) and the minute work index (r = 0.48, P < 0.05). We conclude that insulin-stimulated glucose uptake is decreased in skeletal muscle but increased in proportion to cardiac work in essential hypertension. The increase in heart glucose uptake in mild essential hypertensives with a normal left ventricular mass may reflect increased oxygen consumption and represent an early signal which precedes the development of left ventricular hypertrophy.
authors.affiliation: Department of Medicine, Turku University Cyclotron/PET Center, University of Turku, Finland.
authors.forename: P
authors.initials: P
authors.lastname: Nuutila
authors.forename: M
authors.initials: M
authors.lastname: Mäki
authors.forename: H
authors.initials: H
authors.lastname: Laine
authors.forename: M J
authors.initials: MJ
authors.lastname: Knuuti
authors.forename: U
authors.initials: U
authors.lastname: Ruotsalainen
authors.forename: M
authors.initials: M
authors.lastname: Luotolahti
authors.forename: M
authors.initials: M
authors.lastname: Haaparanta
authors.forename: O
authors.initials: O
authors.lastname: Solin
authors.forename: A
authors.initials: A
authors.lastname: Jula
authors.forename: V A
authors.initials: VA
authors.lastname: Koivisto
mesh_terms: D000328:Adult; D001693:Biological Transport, Active / Q000187:drug effects; D003847:Deoxyglucose / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism*; D006321:Heart / Q000000981:diagnostic imaging / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000378:metabolism*; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000378:metabolism; D007091:Image Processing, Computer-Assisted; D007328:Insulin / Q000494:pharmacology*; D007333:Insulin Resistance; D008297:Male; D018482:Muscle, Skeletal / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism*; D010101:Oxygen Consumption; D014055:Tomography, Emission-Computed; D016277:Ventricular Function, Left
chemical_list: D007328:Insulin; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose; D005947:Glucose